{"id":586508,"date":"2022-02-14T18:00:02","date_gmt":"2022-02-14T18:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=586508"},"modified":"2022-02-14T18:00:02","modified_gmt":"2022-02-14T18:00:02","slug":"angioimmunoblastic-tcell-lymphoma-pipeline-report-current-therapies-emerging-drugs-and-treatment-outlook-key-companies-celgene-verastem-beigene-merck-solasia-pharma-and-kura-oncology","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/angioimmunoblastic-tcell-lymphoma-pipeline-report-current-therapies-emerging-drugs-and-treatment-outlook-key-companies-celgene-verastem-beigene-merck-solasia-pharma-and-kura-oncology_586508.html","title":{"rendered":"Angioimmunoblastic T-Cell Lymphoma Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook | Key Companies &#8211; Celgene, Verastem, Beigene, Merck, Solasia Pharma, and Kura Oncology"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Angioimmunoblastic T-Cell Lymphoma Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook | Key Companies - Celgene, Verastem, Beigene, Merck, Solasia Pharma, and Kura Oncology\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Angioimmunoblastic T-Cell Lymphoma Pipeline Report: Current Therapies, Emerging Drugs, and Treatment Outlook | Key Companies - Celgene, Verastem, Beigene, Merck, Solasia Pharma, and Kura Oncology\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cAngioimmunoblastic T-Cell Lymphoma Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Angioimmunoblastic T-Cell Lymphoma Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Angioimmunoblastic T-Cell Lymphoma Pipeline<\/strong> report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Angioimmunoblastic T-Cell Lymphoma Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/35418ca203a65afbc7caea8941076623.jpg\" alt=\"Angioimmunoblastic T-Cell Lymphoma Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/angioimmunoblastic-t-cell-lymphoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Angioimmunoblastic T-Cell Lymphoma Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Angioimmunoblastic T-Cell Lymphoma<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Angioimmunoblastic T-Cell Lymphoma Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Angioimmunoblastic T-Cell Lymphoma key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Angioimmunoblastic T-Cell Lymphoma Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Angioimmunoblastic T-Cell Lymphoma market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/angioimmunoblastic-t-cell-lymphoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/angioimmunoblastic-t-cell-lymphoma-pipeline-insight<\/a><\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Angioimmunoblastic T-Cell Lymphoma Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The dynamics of the Angioimmunoblastic T-cell Lymphoma (AITL) market is anticipated to change in the coming years owing to the improvement in healthcare spending across the world.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The key companies in the Angioimmunoblastic T-Cell Lymphoma market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Celgene<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Verastem<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Beigene<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Merck<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Solasia Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kura Oncology<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Angioimmunoblastic T-Cell Lymphoma therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Azacitidine (CC-486)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Copiktra (Duvelisib)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tislelizumab (BGB-A317)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SP-02 (darinaparsin)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tipifarnib<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/angioimmunoblastic-t-cell-lymphoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/angioimmunoblastic-t-cell-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Angioimmunoblastic T-Cell Lymphoma&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Angioimmunoblastic T-Cell Lymphoma Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Angioimmunoblastic T-Cell Lymphoma &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Angioimmunoblastic T-Cell Lymphoma Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Angioimmunoblastic T-Cell Lymphoma Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Angioimmunoblastic T-Cell Lymphoma Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Angioimmunoblastic T-Cell Lymphoma Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Angioimmunoblastic T-Cell Lymphoma Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Angioimmunoblastic T-Cell Lymphoma Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Angioimmunoblastic T-Cell Lymphoma Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Angioimmunoblastic T-Cell Lymphoma Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Angioimmunoblastic T-Cell Lymphoma Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/angioimmunoblastic-t-cell-lymphoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/angioimmunoblastic-t-cell-lymphoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Healthcare Report by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dysautonomia-autonomic-dysfunction-market\">Dysautonomia (Autonomic Dysfunction) Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>Dysautonomia (Autonomic Dysfunction) Market<\/strong> is set to evolve in the coming years owing to the rising awareness of the disease, the launch of emerging therapies, and incremental healthcare spending across the world. Globally, some of the key companies such as Celltex Therapeutics, Theravance Biopharma, PTC Therapeutics, and several others are diligently working in the Dysautonomia (Autonomic Dysfunction) Market.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=angioimmunoblastic-tcell-lymphoma-pipeline-report-current-therapies-emerging-drugs-and-treatment-outlook-key-companies-celgene-verastem-beigene-merck-solasia-pharma-and-kura-oncology\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=angioimmunoblastic-tcell-lymphoma-pipeline-report-current-therapies-emerging-drugs-and-treatment-outlook-key-companies-celgene-verastem-beigene-merck-solasia-pharma-and-kura-oncology\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cAngioimmunoblastic T-Cell Lymphoma Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Angioimmunoblastic T-Cell Lymphoma Market. The Angioimmunoblastic T-Cell Lymphoma Pipeline report embraces in-depth commercial and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/angioimmunoblastic-tcell-lymphoma-pipeline-report-current-therapies-emerging-drugs-and-treatment-outlook-key-companies-celgene-verastem-beigene-merck-solasia-pharma-and-kura-oncology_586508.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-586508","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/586508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=586508"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/586508\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=586508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=586508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=586508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}